NASDAQ$KNSA
Kiniksa Pharmaceuticals Ltd · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported strong revenue growth with ARCALYST and clinical trial execution with KPL-404.
Kiniksa Pharmaceuticals reported strong Q3 2023 financial results, highlighted by ARCALYST's net product revenue growth and progress in clinical trials for KPL-404. The company's cash reserves are expected to fund operations into at least 2027.
- ARCALYST Q3 2023 net product revenue was $64.8 million, representing ~94% year-over-year growth.
- KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 is now expected in Q1 2024.
- Cash reserves of $201 million are expected to fund operations into at least 2027.
- Company is currently tracking to the high end of its previously issued guidance of $220 million to $230 million in product revenue.
Headline financials
Revenue & EPS history
Kiniksa · Revenue · Quarterly
$67M
Revenue by segment
Kiniksa · $64.8M total across 1 segment · Q3 2023
- ARCALYST$64.8M+94.0%100.0%
Forward guidance
Kiniksa expects full-year net product revenue to be at the high end of its $220 million to $230 million guidance range.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+5.3%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+7.8%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+45.8%
Q3 2021
Best reaction
-16.6%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.5% | +26.7% | +16.6% | |
| Q4 2025 | -4.7% | -6.1% | -1.3% | |
| Q3 2025 | -2.9% | -8.8% | +4.8% | |
| Q1 2025 | +20.5% | +28.8% | +26.6% | |
| Q4 2024 | +0.5% | +3.3% | +19.0% | |
| Q3 2024 | -16.6% | -18.5% | -19.1% | |
| Q2 2024 | +17.8% | +22.1% | +22.5% | |
| Q1 2024 | +4.4% | +4.6% | +12.1% | |
| Q4 2023 | +1.2% | -3.4% | -5.6% | |
| Q3 2023 | -3.4% | +3.3% | +3.1% | |
| Q2 2023 | +35.2% | +26.8% | +18.1% | |
| Q1 2023 | +24.2% | +24.7% | +29.0% | |
| Q4 2022 | -5.6% | -7.8% | -19.7% | |
| Q3 2022 | +8.6% | +21.7% | +49.3% | |
| Q2 2022 | +17.3% | +29.9% | +14.7% | |
| Q1 2022 | +5.1% | -6.8% | -18.4% | |
| Q4 2021 | -6.8% | -3.4% | -7.2% | |
| Q3 2021 | +45.8% | +41.8% | +8.8% | |
| Q2 2021 | -1.4% | -5.4% | -10.0% | |
| Q1 2021 | -9.0% | -11.4% | -19.4% | |
| Q4 2020 | -6.3% | -11.9% | -28.5% | |
| Q3 2020 | -5.9% | -7.2% | +9.6% | |
| Q2 2020 | +0.8% | -1.2% | -14.7% | |
| Q1 2020 | -7.0% | -9.2% | -0.6% | |
| Q4 2019 | -0.7% | +6.1% | -29.5% | |
| Q3 2019 | +15.7% | +24.5% | +80.8% | |
| Q2 2019 | -2.4% | -12.1% | -9.4% | |
| Q1 2019 | +8.2% | +2.6% | +6.5% | |
| Q4 2018 | -6.1% | -0.2% | +20.2% | |
| Q3 2018 | +11.9% | +5.1% | +6.2% | |
| Q2 2018 | +1.7% | +3.5% | +78.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro